Table 1.
Association analyses between the expression levels of AEG-1 and the clinicopathological characteristics of EOCs
| Variables | Patients (n) | AEG-1 expression
|
P-valuea | |
|---|---|---|---|---|
| Low | High | |||
| All cases | ||||
| Age (years) | ||||
| ≤55 | 82 | 34 | 48 | P=0.031 |
| >55 | 80 | 20 | 60 | |
| Histological type | ||||
| Serous | 118 | 34 | 84 | P=0.061 |
| Nonserous | 44 | 20 | 24 | |
| FIGO stage | ||||
| III | 135 | 53 | 82 | P<0.001 |
| IV | 27 | 1 | 26 | |
| Histological grade | ||||
| G1 | 92 | 52 | 40 | P<0.001 |
| G2/G3 | 70 | 2 | 68 | |
| CA-125 (U mL−1) | ||||
| ≤35 | 55 | 32 | 23 | P<0.001 |
| >35 | 107 | 22 | 85 | |
| Residual tumor (cm) | ||||
| ≤1 | 120 | 53 | 67 | P<0.001 |
| >1 | 42 | 1 | 41 | |
| Lymph node metastasis | ||||
| No | 117 | 45 | 72 | P=0.027 |
| Yes | 45 | 9 | 36 | |
Note:
a
Chi-square test.
Abbreviations: AEG-1, astrocyte-elevated gene-1; CA-125, cancer antigen 125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.